drugset / Trial / NCT01608139
Study of Curcumin, Vorinostat, and Sorafenib
NaSingle-groupOpen-labelTreatment
Summary
The goal of this clinical research study is to learn the highest tolerable dose of the combination of curcumin, vorinostat, and sorafenib that can be given to patients with advanced solid cancer. The safety of this drug combination will also be studied.
Timeline
- Start
- 2012-11
- Primary completion
- 2022-11
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Curcumin | Small molecule | 4 g | Oral |
| Subject | Sorafenib | Small molecule | 200 mg | Oral |
| Subject | Vorinostat | Small molecule | 100 mg | Oral |